Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Gliosarcoma 2Brain Neoplasms 2Recurrence 1Prostatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Metatropic dwarfism 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

etoposide phosphate 2Radiotherapy 2fluorodopa F 18 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Perfusion Magnetic Resonance Imaging 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunologic Techniques 1Immunohistochemistry 1Ifosfamide 1Etoposide 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Doxorubicin 1Donepezil 1Dasatinib 1Cyproheptadine 1Cilengitide 1Carboplatin 1Blotting, Western 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Optic Nerve Glioma × Cilengitide × Clear all
NCT00679354 2018-08-01

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled 19 charts
CNS

Astrocytoma, Oligodendroglioma, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡